Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site

Ja Seung Koo, Woohee Jung, Joon Jeong

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Aims and background. The study was performed to assess the status of immunohistochemical markers in primary andmetastatic breast cancer and to determine the organ-specific characteristics of metastatic breast cancer. Methods. Samples from 13 cases of paired primary and metastatic breast cancer and 34 cases of metastatic breast cancer were included. Results. In the analysis of 13 cases of paired primary andmetastatic breast cancer, estrogen receptor and progesterone receptor loss were noted in 1 (7.7%) case each. Androgen receptor loss and gain was noted in 2 (15.4%) cases, respectively. HER-2 showed 100% concordance with primary and metastatic tumors. C-kit was demonstrated in only 2 (15.4%) cases of metastatic breast cancer. In the analysis of 34 cases of metastatic breast cancer, when classified into triple-negative type (ER-, PR-, and HER-2-), HER-2+ type, and ER+ or PR+/HER-2- type according to immunohistochemical stain results, HER-2 type (66.7%) in brain metastasis and ER+ or PR+/HER-2- type (75.0%) in livermetastasis were predominant. Bonemetastasis was composed of triple negative type (44.4%) and ER+ or PR+/HER-2- type (55.6%), and lung metastasis showed all of three subtypes in similar proportions. Conclusions.Metastatic breast cancer shows different immunohistochemical phenotypes according to metastatic site (P = 0.048).

Original languageEnglish
Pages (from-to)424-432
Number of pages9
JournalTumori
Volume96
Issue number3
Publication statusPublished - 2010 May 1

Fingerprint

Breast Neoplasms
Phenotype
Neoplasm Metastasis
Androgen Receptors
Progesterone Receptors
Estrogen Receptors
Coloring Agents
Lung
Brain
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

@article{882d69d74dff4f7ca750da12f5b3a746,
title = "Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site",
abstract = "Aims and background. The study was performed to assess the status of immunohistochemical markers in primary andmetastatic breast cancer and to determine the organ-specific characteristics of metastatic breast cancer. Methods. Samples from 13 cases of paired primary and metastatic breast cancer and 34 cases of metastatic breast cancer were included. Results. In the analysis of 13 cases of paired primary andmetastatic breast cancer, estrogen receptor and progesterone receptor loss were noted in 1 (7.7{\%}) case each. Androgen receptor loss and gain was noted in 2 (15.4{\%}) cases, respectively. HER-2 showed 100{\%} concordance with primary and metastatic tumors. C-kit was demonstrated in only 2 (15.4{\%}) cases of metastatic breast cancer. In the analysis of 34 cases of metastatic breast cancer, when classified into triple-negative type (ER-, PR-, and HER-2-), HER-2+ type, and ER+ or PR+/HER-2- type according to immunohistochemical stain results, HER-2 type (66.7{\%}) in brain metastasis and ER+ or PR+/HER-2- type (75.0{\%}) in livermetastasis were predominant. Bonemetastasis was composed of triple negative type (44.4{\%}) and ER+ or PR+/HER-2- type (55.6{\%}), and lung metastasis showed all of three subtypes in similar proportions. Conclusions.Metastatic breast cancer shows different immunohistochemical phenotypes according to metastatic site (P = 0.048).",
author = "Koo, {Ja Seung} and Woohee Jung and Joon Jeong",
year = "2010",
month = "5",
day = "1",
language = "English",
volume = "96",
pages = "424--432",
journal = "Tumori",
issn = "0300-8916",
publisher = "Wichtig Publishing",
number = "3",

}

Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site. / Koo, Ja Seung; Jung, Woohee; Jeong, Joon.

In: Tumori, Vol. 96, No. 3, 01.05.2010, p. 424-432.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site

AU - Koo, Ja Seung

AU - Jung, Woohee

AU - Jeong, Joon

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Aims and background. The study was performed to assess the status of immunohistochemical markers in primary andmetastatic breast cancer and to determine the organ-specific characteristics of metastatic breast cancer. Methods. Samples from 13 cases of paired primary and metastatic breast cancer and 34 cases of metastatic breast cancer were included. Results. In the analysis of 13 cases of paired primary andmetastatic breast cancer, estrogen receptor and progesterone receptor loss were noted in 1 (7.7%) case each. Androgen receptor loss and gain was noted in 2 (15.4%) cases, respectively. HER-2 showed 100% concordance with primary and metastatic tumors. C-kit was demonstrated in only 2 (15.4%) cases of metastatic breast cancer. In the analysis of 34 cases of metastatic breast cancer, when classified into triple-negative type (ER-, PR-, and HER-2-), HER-2+ type, and ER+ or PR+/HER-2- type according to immunohistochemical stain results, HER-2 type (66.7%) in brain metastasis and ER+ or PR+/HER-2- type (75.0%) in livermetastasis were predominant. Bonemetastasis was composed of triple negative type (44.4%) and ER+ or PR+/HER-2- type (55.6%), and lung metastasis showed all of three subtypes in similar proportions. Conclusions.Metastatic breast cancer shows different immunohistochemical phenotypes according to metastatic site (P = 0.048).

AB - Aims and background. The study was performed to assess the status of immunohistochemical markers in primary andmetastatic breast cancer and to determine the organ-specific characteristics of metastatic breast cancer. Methods. Samples from 13 cases of paired primary and metastatic breast cancer and 34 cases of metastatic breast cancer were included. Results. In the analysis of 13 cases of paired primary andmetastatic breast cancer, estrogen receptor and progesterone receptor loss were noted in 1 (7.7%) case each. Androgen receptor loss and gain was noted in 2 (15.4%) cases, respectively. HER-2 showed 100% concordance with primary and metastatic tumors. C-kit was demonstrated in only 2 (15.4%) cases of metastatic breast cancer. In the analysis of 34 cases of metastatic breast cancer, when classified into triple-negative type (ER-, PR-, and HER-2-), HER-2+ type, and ER+ or PR+/HER-2- type according to immunohistochemical stain results, HER-2 type (66.7%) in brain metastasis and ER+ or PR+/HER-2- type (75.0%) in livermetastasis were predominant. Bonemetastasis was composed of triple negative type (44.4%) and ER+ or PR+/HER-2- type (55.6%), and lung metastasis showed all of three subtypes in similar proportions. Conclusions.Metastatic breast cancer shows different immunohistochemical phenotypes according to metastatic site (P = 0.048).

UR - http://www.scopus.com/inward/record.url?scp=77954997555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954997555&partnerID=8YFLogxK

M3 - Article

C2 - 20845803

AN - SCOPUS:77954997555

VL - 96

SP - 424

EP - 432

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 3

ER -